The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions however.

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

We were surprised to see the effect only in the Alzheimer’s spectrum and not in other neurodegenerative diseases." ...

The herb rosemary has been linked with memory—now researchers turned the compound against Alzheimer’s disease and cognitive ...

It would help the trials—and patients—if more people were tested for Alzheimer’s earlier on, so that they could be enrolled to try the new drugs. A single register of those with the disease would also ...

The presence of amyloid plaques, sticky substances in the brain, is a hallmark of Alzheimer’s disease — though the role it plays is a matter of debate among neurologists. The FDA has approved ...

Anti-amyloid medications can help treat people in the early stages of Alzheimer’s by removing amyloid plaques from the brain. Although they’re not a cure for Alzheimer’s, they may help slow ...

Get Instant Summarized Text (Gist) Analysis of four anti-amyloid drugs shows that lecanemab binds most effectively to small, soluble amyloid beta aggregates, which form early in Alzheimer's disease.